Global Thawing Equipment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Thawing Equipment Market Overview

The Thawing Equipment Market was valued at USD 240.38 billion in 2025 and is projected to reach USD 428.71 billion by 2033, growing at a CAGR of 7.50% from 2026 to 2033. The market is experiencing consistent growth driven by the rising demand for advanced bioprocessing and laboratory equipment, increasing adoption of frozen biologics and cell-based therapies, and expanding applications across pharmaceutical, biotechnology, blood banking, and research laboratories. Growing investments in regenerative medicine, biopharmaceutical manufacturing, and vaccine development are significantly supporting the adoption of advanced thawing technologies globally.

The increasing use of cryopreserved blood products, stem cells, embryos, plasma, and biologics, combined with stringent regulatory requirements for sample integrity and temperature-controlled processing, is compelling healthcare facilities, biobanks, and research organizations to adopt advanced thawing equipment solutions. Automated and rapid thawing systems are increasingly replacing conventional manual thawing methods in many facilities, offering improved temperature uniformity, reduced contamination risk, enhanced process efficiency, and reliable preservation of sensitive biological materials required for clinical diagnostics, cell therapy manufacturing, and pharmaceutical research applications.

Key Market Trends & Insights

• North America dominated the Thawing Equipment Market with the largest revenue share of 38.64% in 2025, supported by advanced healthcare infrastructure, increasing adoption of biobanking and cryopreservation technologies, strong investments in regenerative medicine, and the presence of leading biotechnology and pharmaceutical companies across the region. Growing demand for safe thawing of blood products, stem cells, and biological samples, along with rising cell and gene therapy research activities, is further supporting market expansion across the U.S. and Canada.
• The Automatic segment dominated the market with a revenue share of 58.74% in 2025 due to the increasing demand for standardized, contamination-free, and high-throughput thawing processes across blood banks, biopharmaceutical companies, and clinical laboratories
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.4% from 2026 to 2033, fueled by expanding healthcare infrastructure, increasing investments in biotechnology and pharmaceutical research, rising stem cell banking activities, and growing adoption of advanced laboratory technologies across China, India, Japan, and South Korea. Increasing government support for regenerative medicine and biobanking initiatives is further accelerating regional market growth.
• The Stem Cells sample segment is projected to register the fastest growth at a CAGR of 7.1% from 2026 to 2033, reflecting the growing demand for stem cell therapies, regenerative medicine research, and cryopreserved cellular products. Increasing clinical trials involving stem cells and rising investments in cell-based therapeutics are significantly supporting segment expansion globally.
• The Blood Products segment dominated the sample category with a 36.87% revenue share in 2025, supported by extensive use of thawing equipment in blood banks, transfusion centers, and hospitals for safe thawing of plasma and other blood components. Rising incidence of chronic diseases, trauma cases, and surgical procedures requiring blood transfusions continues to strengthen demand for reliable thawing systems.
• Hospitals and Transfusion Centers accounted for 34.28% of the market in 2025, driven by increasing patient admissions, growing blood transfusion procedures, rising adoption of automated thawing systems, and strong focus on maintaining sample integrity and patient safety during transfusion and therapeutic procedures.
• The Research Applications segment is the fastest-growing application category, with a CAGR of 6.9% from 2026 to 2033, driven by expanding biomedical research activities, increasing use of cryopreserved biological samples, and growing investments in genomics, cell biology, and regenerative medicine research worldwide.

Market Size & Forecast

• Global Market Value (2025): USD 240.38 Billion
• Expected Market Value (2033): USD 428.71 Billion
• Forecast CAGR (2026–2033): 7.50%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Thawing Equipment Market Segmentation

Thawing Equipment Market Trends

Trend: Growing Adoption of Automated and Temperature-Controlled Bioprocessing Systems

Healthcare organizations, biobanks, pharmaceutical manufacturers, and research laboratories are increasingly adopting advanced thawing equipment to improve sample integrity, operational efficiency, and temperature-sensitive biological processing workflows. Automated thawing systems equipped with digital temperature monitoring, programmable controls, and contamination-reduction technologies are increasingly replacing traditional manual water-bath thawing methods in blood banks and biopharmaceutical facilities. The growing use of cryopreserved plasma, stem cells, embryos, tissues, and cellular therapeutics is accelerating the demand for high-precision thawing technologies capable of maintaining sample viability and regulatory compliance. For instance, blood banks globally process millions of plasma units annually that require controlled thawing procedures before transfusion. In addition, the rapid expansion of regenerative medicine and cell therapy manufacturing has significantly increased demand for automated thawing systems integrated with closed-system bioprocessing workflows. Advanced thawing platforms are also being increasingly utilized in IVF clinics and stem cell research centers where accurate thawing conditions are critical for maintaining cellular functionality and improving clinical outcomes.

Thawing Equipment Market Dynamics

Key Market Driver: Rising Demand for Cryopreservation and Cell-Based Therapies

The rapid expansion of regenerative medicine, biobanking, blood transfusion services, and cell & gene therapy development is significantly driving demand for advanced thawing equipment globally. Pharmaceutical and biotechnology companies are increasingly utilizing automated thawing systems for stem cells, CAR-T therapies, plasma products, and cryopreserved biological materials to ensure sample stability and process consistency. According to industry estimates, global investments in cell and gene therapy manufacturing have increased substantially over the last five years, creating strong demand for reliable thawing technologies capable of supporting temperature-sensitive workflows. Hospitals, blood banks, and research institutions are also adopting advanced thawing systems to improve operational efficiency, reduce contamination risks, and maintain compliance with stringent laboratory standards. Automated thawing solutions with digital controls and uniform temperature distribution are enabling healthcare facilities to reduce manual intervention while improving sample recovery rates and processing accuracy. In addition, the increasing volume of organ transplantation procedures and frozen plasma utilization is further strengthening demand for advanced thawing equipment across clinical and therapeutic applications.

Key Restraint/Challenge: High Cost and Operational Complexity of Advanced Thawing Systems

A major challenge in the Thawing Equipment Market is the high acquisition and maintenance cost associated with automated and high-capacity thawing systems. Advanced thawing equipment integrates precision heating technologies, automated monitoring systems, digital interfaces, and contamination-control mechanisms, resulting in substantial capital investment for healthcare providers and laboratory operators. The total cost of ownership also includes equipment validation, maintenance, calibration, consumables, and software upgrades, limiting adoption among smaller laboratories, fertility clinics, and emerging-market healthcare institutions.

In addition, handling cryopreserved biological materials requires trained personnel and strict adherence to quality assurance protocols to avoid sample degradation or contamination during thawing procedures. For instance, advanced automated plasma thawing systems and cell therapy thawing platforms used in large-scale biopharmaceutical manufacturing facilities can cost significantly more than conventional manual systems, creating affordability challenges for resource-constrained organizations. Regulatory compliance requirements related to blood handling, tissue preservation, and biologics processing further add to operational complexity across healthcare and research facilities.

Key Market Opportunity: Integration of Smart Monitoring and Automated Bioprocessing Technologies

The integration of artificial intelligence, IoT-enabled monitoring systems, and automated bioprocessing technologies presents a major growth opportunity for the Thawing Equipment Market. Smart thawing platforms equipped with real-time temperature sensors, cloud-based monitoring, automated alerts, and digital workflow management systems are improving operational accuracy, traceability, and sample safety across laboratories and healthcare facilities. AI-enabled monitoring systems can optimize thawing cycles, reduce processing errors, and improve consistency in handling sensitive biological materials.

In addition, growing adoption of closed-system bioprocessing solutions and automated laboratory workflows is creating strong demand for next-generation thawing equipment integrated with pharmaceutical manufacturing and cryogenic storage systems. Expanding investments in biobanking infrastructure, stem cell preservation programs, and personalized medicine initiatives across Asia-Pacific, Latin America, and the Middle East are further expected to create substantial growth opportunities for advanced thawing equipment manufacturers over the coming years.

Thawing Equipment Market Scope

The Thawing Equipment market is segmented on the basis of product, sample, end user, and application.

• By Product

On the basis of product, the Thawing Equipment Market is segmented into manual and automatic thawing equipment. The Automatic segment dominated the market with a revenue share of 58.74% in 2025 due to the increasing demand for standardized, contamination-free, and high-throughput thawing processes across blood banks, biopharmaceutical companies, and clinical laboratories. Automatic thawing systems provide precise temperature control, improved sample integrity, and reduced manual intervention, making them highly suitable for critical healthcare and research applications. These systems are widely utilized for thawing plasma, stem cells, cryopreserved tissues, and biologics in hospitals and research institutions where maintaining sample viability is essential. In addition, rising investments in regenerative medicine, cell therapy manufacturing, and advanced biobanking infrastructure are accelerating adoption of automated thawing solutions globally. The integration of digital monitoring systems, touchscreen interfaces, automated alarms, and programmable thawing protocols is further improving operational efficiency and reducing human error. Pharmaceutical manufacturers are increasingly deploying automated thawing systems in biologics production and vaccine development workflows to ensure process consistency and regulatory compliance. Growing emphasis on laboratory automation and increasing demand for high-volume sample processing are further supporting segment dominance. Moreover, stringent quality standards for blood transfusion and cell-based therapeutics continue to reinforce the widespread adoption of automatic thawing equipment across developed healthcare markets.

The Automatic segment is also expected to witness the fastest CAGR of 7.4% from 2026 to 2033, driven by growing adoption of automated laboratory workflows, increasing demand for precision thawing technologies, and rising investments in advanced healthcare infrastructure. Healthcare facilities and biopharmaceutical companies are increasingly adopting intelligent thawing systems integrated with real-time monitoring, AI-assisted controls, and temperature validation features to improve operational safety and sample consistency. Rising demand for stem cell therapies, CAR-T cell manufacturing, and cryopreserved biologics is further creating strong growth opportunities for automated thawing platforms. In addition, technological advancements in dry thawing systems and water-free thawing technologies are improving efficiency while minimizing contamination risks. Expanding biobank networks across Asia-Pacific and Europe are also contributing to rising demand for scalable automatic thawing solutions. Furthermore, increasing regulatory focus on sample traceability, process reproducibility, and laboratory quality assurance is expected to accelerate long-term market expansion for advanced automatic thawing equipment globally.

• By Sample

On the basis of sample, the Thawing Equipment Market is segmented into blood products, ovum/embryo, semen, human tissue samples, organs, stem cells, and other samples. The Blood Products segment dominated the market with a share of 34.62% in 2025 due to the extensive utilization of thawing equipment in blood banks, trauma centers, hospitals, and transfusion facilities worldwide. Increasing demand for plasma transfusions, cryopreserved blood components, and emergency care services is significantly driving adoption of advanced blood thawing systems. Blood thawing equipment enables rapid and controlled thawing of fresh frozen plasma while maintaining protein stability and minimizing contamination risks. Rising prevalence of chronic diseases, trauma injuries, surgical procedures, and organ transplantation activities has increased the need for reliable blood storage and thawing infrastructure globally. In addition, healthcare institutions are increasingly replacing conventional water bath systems with automated dry thawing technologies to improve safety and operational efficiency. Growing investments in transfusion medicine and blood banking modernization programs are further supporting market growth. Regulatory requirements regarding safe handling of blood products and increasing awareness regarding infection prevention are reinforcing demand for advanced thawing technologies. Furthermore, expanding healthcare access and rising emergency preparedness initiatives across developing countries continue to strengthen segment dominance.

The Stem Cells segment is anticipated to register the fastest CAGR of 7.8% from 2026 to 2033, driven by the rapid expansion of regenerative medicine, stem cell therapy research, and personalized medicine applications. Increasing clinical adoption of stem-cell-based treatments for cancer, neurological disorders, autoimmune diseases, and orthopedic conditions is creating substantial demand for high-precision thawing systems capable of preserving cellular viability. Biopharmaceutical companies and research laboratories are increasingly investing in automated thawing platforms designed specifically for cryopreserved stem cells and cell-based therapeutics. In addition, rising government funding for stem cell research and increasing commercialization of regenerative medicine products are accelerating market expansion. Advanced thawing systems equipped with programmable temperature control and contamination-free processing capabilities are becoming critical for maintaining therapeutic efficacy. Growing establishment of stem cell banks and expansion of cryopreservation infrastructure across Asia-Pacific and North America are also supporting strong segment growth. Moreover, increasing clinical trials involving stem-cell-based therapies are expected to further boost adoption of next-generation thawing equipment during the forecast period.

• By End User

On the basis of end user, the Thawing Equipment Market is segmented into blood banks and transfusion centers, hospitals, research laboratories, pharmaceutical industry, biobanks, and gene banks. The Blood Banks and Transfusion Centers segment dominated the market with a revenue share of 36.48% in 2025 owing to the growing global demand for safe blood storage, plasma management, and emergency transfusion services. Blood banks require reliable thawing equipment to ensure rapid preparation of plasma and cryopreserved blood products while maintaining compliance with strict healthcare safety regulations. Increasing incidence of trauma cases, surgeries, chronic diseases, and hematological disorders has significantly increased transfusion requirements worldwide. In addition, governments and healthcare organizations are investing heavily in blood banking modernization and cold chain management infrastructure to improve transfusion efficiency and patient safety. Automated plasma thawing systems are increasingly being adopted due to their ability to provide standardized thawing conditions and reduce contamination risks. Growing awareness regarding infection control and the rising need for emergency preparedness are further supporting segment growth. Technological advancements such as dry thawing systems, touchscreen monitoring, and programmable workflows are improving operational productivity within blood centers. Furthermore, expanding voluntary blood donation programs and rising healthcare expenditure across emerging economies continue to reinforce the dominance of this segment in the global market.

The Biobanks segment is projected to witness the fastest CAGR of 7.6% from 2026 to 2033, driven by the rapid expansion of biobanking activities, genomic research programs, and precision medicine initiatives globally. Biobanks are increasingly storing cryopreserved biological materials including tissues, stem cells, plasma, DNA samples, and organ specimens, creating substantial demand for advanced thawing technologies. Research institutions and pharmaceutical companies are investing heavily in automated thawing systems to improve sample integrity, traceability, and workflow standardization. In addition, growing focus on personalized medicine, biomarker discovery, and large-scale clinical research is accelerating the establishment of modern biobank infrastructure across North America, Europe, and Asia-Pacific. Advanced thawing equipment helps maintain biological sample quality while minimizing contamination and processing variability. Increasing collaborations between research organizations, hospitals, and biotechnology firms are also supporting strong market expansion. Furthermore, rising government funding for biomedical research and increasing adoption of AI-integrated laboratory automation systems are expected to further drive demand for thawing equipment within biobanks during the forecast period.

• By Application

On the basis of application, the Thawing Equipment Market is segmented into therapeutic applications, research applications, clinical trials, and other applications. The Therapeutic Applications segment dominated the market with a share of 39.81% in 2025 due to the extensive use of thawing equipment in blood transfusions, regenerative medicine, cell therapy manufacturing, and organ transplantation procedures. Hospitals, transfusion centers, and biopharmaceutical companies require highly controlled thawing systems to maintain viability and functionality of cryopreserved therapeutic products. Increasing prevalence of cancer, chronic diseases, and hematological disorders has accelerated the demand for plasma therapies, stem cell transplantation, and advanced biologics. In addition, growing commercialization of cell and gene therapies is significantly increasing the need for high-precision thawing technologies capable of supporting critical therapeutic workflows. Healthcare providers are increasingly adopting automated thawing systems to improve treatment consistency, minimize contamination risks, and ensure regulatory compliance. Rising investments in advanced healthcare infrastructure and personalized medicine programs are further strengthening segment growth. Furthermore, technological advancements including dry thawing platforms, automated temperature validation, and contamination-free thawing processes are enhancing operational efficiency and patient safety across therapeutic applications globally.

The Clinical Trials segment is expected to register the fastest CAGR of 7.3% from 2026 to 2033, driven by the rapid increase in biologics development, regenerative medicine trials, and advanced cell therapy research worldwide. Pharmaceutical and biotechnology companies are increasingly conducting clinical studies involving cryopreserved biologics, stem cells, plasma-derived therapies, and gene therapies, creating strong demand for reliable thawing solutions. Clinical trial organizations require advanced thawing equipment to maintain sample integrity, improve reproducibility, and ensure compliance with stringent regulatory standards. In addition, rising investments in precision medicine research and increasing global clinical trial activity are supporting market expansion. Automated thawing technologies integrated with digital monitoring and data logging capabilities are improving workflow accuracy and traceability in research settings. Expanding partnerships between contract research organizations, hospitals, and biopharmaceutical firms are also contributing to growing adoption of advanced thawing platforms. Moreover, increasing demand for decentralized clinical trials and personalized therapeutic development is expected to accelerate the use of next-generation thawing equipment across global clinical research programs.

Thawing Equipment Market Regional Analysis

North America dominated the Thawing Equipment market and accounted for the largest revenue share of 38.64% in 2025, supported by advanced healthcare infrastructure, increasing adoption of biobanking and cryopreservation technologies, and strong investments in regenerative medicine and cell therapy research. The region benefits from the strong presence of leading biotechnology companies, pharmaceutical manufacturers, blood banks, and research organizations across the U.S. and Canada. Growing demand for safe thawing of blood products, stem cells, plasma, tissues, and biological samples is significantly driving the adoption of advanced thawing systems throughout the region. In addition, increasing clinical use of cell and gene therapies, rising organ transplantation procedures, and expanding biopharmaceutical manufacturing activities are accelerating demand for automated thawing technologies. Healthcare institutions are increasingly adopting contamination-free dry thawing systems and AI-enabled monitoring platforms to improve sample safety and workflow efficiency. Furthermore, favorable government funding for biomedical research and rising investments in advanced laboratory automation technologies continue to strengthen North America’s leadership position in the Thawing Equipment Market.

U.S. Thawing Equipment Market Insight

The U.S. Thawing Equipment market is witnessing strong growth due to rising investments in regenerative medicine, stem cell therapy research, and advanced biopharmaceutical manufacturing. The country’s highly developed healthcare ecosystem and strong presence of biotechnology companies, blood banks, and research laboratories are significantly supporting demand for advanced thawing solutions. Increasing adoption of cryopreserved biologics, plasma products, stem cells, and CAR-T therapies is accelerating the need for high-precision thawing equipment across hospitals and pharmaceutical facilities. In addition, growing government support for cell and gene therapy development, along with rising investments in clinical research infrastructure, is contributing to market expansion. Healthcare providers are increasingly deploying automated dry thawing systems with real-time temperature monitoring and contamination control features to improve patient safety and operational efficiency. Furthermore, rising demand for biobanking and precision medicine applications continues to drive innovation and adoption of advanced thawing technologies across the U.S. healthcare sector.

Europe Thawing Equipment Market Insight

The Europe Thawing Equipment market remains a major contributor to global revenue, driven by strong government support for biomedical research, increasing adoption of cryopreservation technologies, and rising demand for advanced laboratory equipment. Countries across the region are investing heavily in regenerative medicine programs, blood banking modernization, and biopharmaceutical manufacturing infrastructure, supporting steady market growth. Increasing utilization of thawing equipment in plasma processing, tissue preservation, stem cell storage, and organ transplantation activities is further strengthening market demand. In addition, the presence of established pharmaceutical manufacturers, biotechnology firms, and academic research institutes is contributing to rising adoption of automated thawing systems. Healthcare facilities are increasingly replacing conventional water bath thawing methods with dry thawing technologies to minimize contamination risks and improve workflow standardization. Furthermore, stringent healthcare quality regulations and increasing focus on laboratory automation continue to enhance the adoption of thawing equipment across Europe.

U.K. Thawing Equipment Market Insight

The U.K. Thawing Equipment market is experiencing steady growth, supported by increasing investments in biotechnology research, regenerative medicine, and advanced healthcare technologies. Hospitals, blood banks, and pharmaceutical companies are increasingly utilizing automated thawing systems for safe handling of cryopreserved plasma, stem cells, tissues, and biologics. Growing focus on cell therapy commercialization and precision medicine research is significantly driving demand for contamination-free thawing technologies across the country. In addition, rising adoption of laboratory automation and digital monitoring systems is improving operational efficiency in clinical and research laboratories. Government support for biomedical innovation and increasing collaborations between academic institutions and biotechnology firms are also contributing to market expansion. Furthermore, the expansion of biobanking activities and increasing clinical trials involving cell-based therapies continue to strengthen demand for advanced thawing equipment throughout the U.K.

Germany Thawing Equipment Market Insight

The Germany Thawing Equipment market is expanding steadily due to the country’s advanced pharmaceutical manufacturing capabilities, strong biomedical research ecosystem, and growing adoption of regenerative medicine technologies. German hospitals, research institutions, and biotechnology companies are increasingly deploying advanced thawing systems for blood products, stem cells, tissues, and cryopreserved biologics. Rising investments in biopharmaceutical production, cell therapy research, and laboratory automation are significantly supporting market growth. In addition, increasing emphasis on precision medicine and advanced clinical diagnostics is accelerating demand for reliable and contamination-free thawing technologies. Healthcare providers are increasingly adopting automated thawing systems integrated with digital monitoring and quality assurance capabilities to improve sample integrity and operational safety. Furthermore, strong government support for biotechnology innovation and healthcare modernization continues to reinforce Germany’s position as a key market for thawing equipment in Europe.

Asia-Pacific Thawing Equipment Market Insight

The Asia-Pacific Thawing Equipment market is expected to witness rapid growth and is projected to register the fastest CAGR of 7.4% from 2026 to 2033, driven by expanding healthcare infrastructure, increasing investments in biotechnology and pharmaceutical research, and growing adoption of advanced laboratory technologies across China, India, Japan, and South Korea. Rising stem cell banking activities, increasing blood transfusion demand, and growing regenerative medicine research programs are significantly accelerating market expansion throughout the region. Governments across Asia-Pacific are increasingly supporting biobanking initiatives and precision medicine programs, creating substantial opportunities for advanced thawing equipment manufacturers. In addition, increasing establishment of pharmaceutical manufacturing facilities and contract research organizations is driving demand for automated thawing systems. Healthcare institutions are increasingly adopting contamination-free thawing technologies to improve sample quality and workflow efficiency. Furthermore, rising awareness regarding laboratory safety standards and increasing healthcare expenditure continue to support long-term regional market growth.

Japan Thawing Equipment Market Insight

The Japan Thawing Equipment market is witnessing consistent growth due to rising investments in regenerative medicine, stem cell therapy development, and advanced healthcare technologies. Japanese pharmaceutical companies, hospitals, and research institutes are increasingly adopting high-precision thawing systems for cryopreserved tissues, plasma products, and stem cell samples. The country’s strong focus on biomedical innovation and personalized medicine is significantly driving adoption of advanced thawing technologies across clinical and research settings. In addition, increasing demand for contamination-free laboratory workflows and automated cryopreservation systems is supporting market growth. Government initiatives promoting cell therapy commercialization and advanced biopharmaceutical manufacturing are also contributing to rising equipment adoption. Furthermore, integration of digital monitoring technologies and laboratory automation platforms is improving operational accuracy and supporting continued market expansion in Japan.

China Thawing Equipment Market Insight

The China Thawing Equipment market is growing rapidly, driven by expanding healthcare infrastructure, rising biotechnology investments, and increasing government focus on regenerative medicine and biopharmaceutical innovation. The country is witnessing growing demand for advanced thawing systems across blood banks, hospitals, pharmaceutical companies, and research laboratories due to increasing use of cryopreserved biological samples and plasma products. Rapid expansion of stem cell banking activities and increasing clinical trials involving cell-based therapies are significantly supporting market growth. In addition, rising adoption of automated laboratory technologies and increasing investments in precision medicine research are accelerating deployment of advanced thawing equipment across healthcare facilities. Chinese biotechnology firms are increasingly investing in contamination-free thawing technologies integrated with digital monitoring systems to improve operational efficiency and regulatory compliance. Furthermore, favorable government policies supporting biomedical research and healthcare modernization are positioning China as one of the fastest-growing thawing equipment markets globally.

Thawing Equipment Market Share

The Thawing Equipment industry is primarily led by well-established companies, including:

• Helmer Scientific (U.S.)
• Sarstedt AG & Co. KG (Germany)
• Barkey GmbH & Co. KG (Germany)
• Boekel Scientific (U.S.)
• Cytiva (U.S.)
• Cardinal Health, Inc. (U.S.)
• THERMOGENESIS Holdings, Inc. (U.S.)
• GE HealthCare Technologies Inc. (U.S.)
• Eppendorf SE (Germany)
• Biolife Solutions, Inc. (U.S.)
• Fisher Scientific International Inc. (U.S.)
• Merck KGaA (Germany)
• Avantor, Inc. (U.S.)
• Sartorius AG (Germany)
• PHC Holdings Corporation (Japan)
• Chart Industries, Inc. (U.S.)
• Brooks Automation, Inc. (U.S.)
• Custom Biogenic Systems (CBS) (U.S.)
• CellPoint Scientific, Inc. (U.S.)
• Planer PLC (U.K.)
• Labcold Ltd. (U.K.)
• Friocell S.A. (Spain)
• Arthrex, Inc. (U.S.)
• KW Apparecchi Scientifici S.r.l. (Italy)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• TERUMO BCT, Inc. (U.S.)
• Haier Biomedical (China)
• Grant Instruments (U.K.)
• Air Science USA LLC (U.S.)
• Memmert GmbH + Co. KG (Germany)

Latest Developments in Thawing Equipment Market

• In April 2025, BioLife Solutions expanded the commercial availability of its ThawSTAR® CB platform for automated cryobag thawing in cell and gene therapy manufacturing. The system incorporates automated biosample sensing technology, real-time temperature analytics, and water-free thawing capabilities to improve reproducibility and reduce contamination risks during thawing workflows for cryopreserved biologics and cell therapies
• In January 2024, Cytiva expanded its VIA Thaw platform by introducing a GMP-compliant thawing solution designed for commercial-scale cell therapy manufacturing. The upgraded system integrates enhanced automation, real-time temperature monitoring, and digital data logging features to support large-scale regenerative medicine and biopharmaceutical production workflows
• In October 2023, Barkey GmbH & Co. KG strengthened its plasma thawing equipment portfolio with advanced Plasmatherm systems capable of rapid and uniform thawing of fresh frozen plasma, cryoprecipitate, and infusion products. The system introduced improved dry-thawing technology, programmable cycle controls, and enhanced contamination prevention features for blood banks and transfusion centers
• In June 2023, Helmer Scientific expanded adoption of its QuickThaw® Plasma Thawing Systems across hospitals and blood banks to support increasing transfusion requirements and blood product management. The systems utilize controlled temperature regulation and agitation-based thawing technology to reduce thaw times while maintaining plasma integrity and transfusion safety standards
• In September 2022, researchers published successful experimental results demonstrating ultrasonic rewarming technology for cryopreserved biological samples, achieving thawing rates significantly faster than traditional thermal conduction methods. The development highlighted the growing innovation in rapid thawing technologies for regenerative medicine, tissue engineering, and cryobiology applications
• In August 2022, GenesisBPS promoted broader clinical adoption of its ZipThaw® dry thawing platform for thawing fresh frozen plasma, stem cells, and cryopreserved biologics. The system provides precise temperature tracking, contamination reduction, and FDA-cleared thawing capabilities to support transfusion medicine and cell therapy workflows
• In May 2021, Sarstedt AG & Co. KG expanded deployment of its SAHARA-III plasma thawing units designed for rapid and contactless thawing of blood products using infrared temperature sensing technology. The equipment supports simultaneous thawing of multiple blood bags while improving operational efficiency and safety in transfusion laboratories

SKU-55715